Annual CFF
$1.07 M
-$8.51 M-88.85%
December 31, 2023
Summary
- As of February 26, 2025, ONCT annual cash flow from financing activities is $1.07 million, with the most recent change of -$8.51 million (-88.85%) on December 31, 2023.
- During the last 3 years, ONCT annual CFF has fallen by -$113.11 million (-99.06%).
- ONCT annual CFF is now -99.06% below its all-time high of $114.18 million, reached on December 31, 2020.
Performance
ONCT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
$0.000.00%
September 30, 2024
Summary
- As of February 26, 2025, ONCT quarterly cash flow from financing activities is $0.00, unchanged on September 30, 2024.
- Over the past year, ONCT quarterly CFF has stayed the same.
- ONCT quarterly CFF is now -100.00% below its all-time high of $99.39 million, reached on December 31, 2020.
Performance
ONCT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$88.00 K
+$49.00 K+35.77%
September 30, 2024
Summary
- As of February 26, 2025, ONCT TTM cash flow from financing activities is -$88.00 thousand, with the most recent change of +$49.00 thousand (+35.77%) on September 30, 2024.
- Over the past year, ONCT TTM CFF has stayed the same.
- ONCT TTM CFF is now -100.08% below its all-time high of $114.64 million, reached on March 31, 2021.
Performance
ONCT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ONCT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -88.8% | 0.0% | 0.0% |
| 3 y3 years | -99.1% | -100.0% | -100.8% |
| 5 y5 years | -95.5% | -100.0% | -100.8% |
ONCT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -88.8% | +73.1% | -100.0% | +100.0% | -100.8% | +36.2% |
| 5 y | 5-year | -99.1% | +7020.0% | -100.0% | +100.0% | -100.1% | +36.2% |
| alltime | all time | -99.1% | -100.0% | -100.0% | +100.0% | -100.1% | +58.1% |
Oncternal Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(0.0%) | -$88.00 K(-35.8%) |
| Jun 2024 | - | $0.00(-100.0%) | -$137.00 K(-0.7%) |
| Mar 2024 | - | -$87.00 K(+8600.0%) | -$138.00 K(-112.9%) |
| Dec 2023 | $1.07 M(-88.9%) | -$1000.00(-98.0%) | $1.07 M(-65.4%) |
| Sep 2023 | - | -$49.00 K(+4800.0%) | $3.08 M(-54.8%) |
| Jun 2023 | - | -$1000.00(-100.1%) | $6.83 M(-36.2%) |
| Mar 2023 | - | $1.12 M(-44.4%) | $10.70 M(+11.7%) |
| Dec 2022 | $9.58 M(+1452.5%) | $2.01 M(-45.5%) | $9.58 M(+26.6%) |
| Sep 2022 | - | $3.69 M(-4.6%) | $7.57 M(+90.6%) |
| Jun 2022 | - | $3.87 M(>+9900.0%) | $3.97 M(+2412.0%) |
| Mar 2022 | - | $0.00(-100.0%) | $158.00 K(-74.4%) |
| Dec 2021 | $617.00 K(-99.5%) | $1000.00(-99.0%) | $617.00 K(-99.4%) |
| Sep 2021 | - | $97.00 K(+61.7%) | $100.00 M(-9.0%) |
| Jun 2021 | - | $60.00 K(-86.9%) | $109.88 M(-4.2%) |
| Mar 2021 | - | $459.00 K(-99.5%) | $114.64 M(+0.4%) |
| Dec 2020 | $114.18 M(>+9900.0%) | $99.39 M(+897.0%) | $114.18 M(+671.9%) |
| Sep 2020 | - | $9.97 M(+106.9%) | $14.79 M(+205.9%) |
| Jun 2020 | - | $4.82 M(>+9900.0%) | $4.84 M(>+9900.0%) |
| Mar 2020 | - | $4000.00(>+9900.0%) | $19.00 K(+26.7%) |
| Dec 2019 | $15.00 K(-99.9%) | $0.00(-100.0%) | $15.00 K(0.0%) |
| Sep 2019 | - | $13.00 K(+550.0%) | $15.00 K(-80.3%) |
| Jun 2019 | - | $2000.00(>+9900.0%) | $76.00 K(-99.7%) |
| Mar 2019 | - | $0.00(0.0%) | $24.55 M(+2.7%) |
| Dec 2018 | $23.91 M(-47.5%) | $0.00(-100.0%) | $23.91 M(0.0%) |
| Sep 2018 | - | $74.00 K(-99.7%) | $23.91 M(-65.6%) |
| Jun 2018 | - | $24.47 M(-3906.2%) | $69.48 M(+54.4%) |
| Mar 2018 | - | -$643.00 K(<-9900.0%) | $45.01 M(-1.1%) |
| Dec 2017 | $45.49 M(+237.5%) | $0.00(-100.0%) | $45.49 M(-23.1%) |
| Sep 2017 | - | $45.65 M(>+9900.0%) | $59.18 M(+337.3%) |
| Jun 2017 | - | $0.00(-100.0%) | $13.54 M(0.0%) |
| Mar 2017 | - | -$156.00 K(-101.1%) | $13.54 M(+0.4%) |
| Dec 2016 | $13.48 M(>+9900.0%) | $13.69 M(>+9900.0%) | $13.48 M(-6519.5%) |
| Sep 2016 | - | $0.00(0.0%) | -$210.00 K(0.0%) |
| Jun 2016 | - | $0.00(-100.0%) | -$210.00 K(0.0%) |
| Mar 2016 | - | -$210.00 K(<-9900.0%) | -$210.00 K(<-9900.0%) |
| Dec 2015 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Jun 2015 | - | $0.00(0.0%) | $42.81 M(+1.5%) |
| Mar 2015 | - | $0.00(-100.0%) | $42.19 M(-33.4%) |
| Dec 2014 | $63.33 M(+5095.2%) | $42.81 M(>+9900.0%) | $63.33 M(+208.7%) |
| Sep 2014 | - | $0.00(-100.0%) | $20.51 M(-1.7%) |
| Jun 2014 | - | -$623.00 K(-102.9%) | $20.87 M(-6.3%) |
| Mar 2014 | - | $21.14 M(<-9900.0%) | $22.27 M(+1727.2%) |
| Dec 2013 | $1.22 M | -$2000.00(-100.6%) | $1.22 M(+0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2013 | - | $356.00 K(-54.4%) | $1.21 M(+42.4%) |
| Jun 2013 | - | $781.00 K(+829.8%) | $849.00 K(+1247.6%) |
| Mar 2013 | - | $84.00 K(-800.0%) | $63.00 K(+2000.0%) |
| Dec 2012 | $3000.00(-100.0%) | -$12.00 K(+200.0%) | $3000.00(-142.9%) |
| Sep 2012 | - | -$4000.00(-20.0%) | -$7000.00(-82.9%) |
| Jun 2012 | - | -$5000.00(-120.8%) | -$41.00 K(-100.1%) |
| Mar 2012 | - | $24.00 K(-209.1%) | $49.00 M(+0.1%) |
| Dec 2011 | $48.95 M(+21.7%) | -$22.00 K(-42.1%) | $48.95 M(-45.2%) |
| Sep 2011 | - | -$38.00 K(-100.1%) | $89.25 M(-0.0%) |
| Jun 2011 | - | $49.03 M(<-9900.0%) | $89.27 M(+122.0%) |
| Mar 2011 | - | -$21.00 K(-100.1%) | $40.21 M(+0.0%) |
| Dec 2010 | $40.21 M(>+9900.0%) | $40.28 M(<-9900.0%) | $40.21 M(<-9900.0%) |
| Sep 2010 | - | -$21.00 K(+5.0%) | -$69.00 K(+137.9%) |
| Jun 2010 | - | -$20.00 K(-23.1%) | -$29.00 K(-163.0%) |
| Mar 2010 | - | -$26.00 K(+1200.0%) | $46.00 K(-64.9%) |
| Dec 2009 | $131.00 K(-88.7%) | -$2000.00(-110.5%) | $131.00 K(-61.0%) |
| Sep 2009 | - | $19.00 K(-65.5%) | $336.00 K(-52.8%) |
| Jun 2009 | - | $55.00 K(-6.8%) | $712.00 K(-34.7%) |
| Mar 2009 | - | $59.00 K(-70.9%) | $1.09 M(-6.1%) |
| Dec 2008 | $1.16 M(-94.2%) | $203.00 K(-48.6%) | $1.16 M(-94.2%) |
| Sep 2008 | - | $395.00 K(-9.0%) | $20.19 M(+0.5%) |
| Jun 2008 | - | $434.00 K(+233.8%) | $20.08 M(+1.7%) |
| Mar 2008 | - | $130.00 K(-99.3%) | $19.74 M(-1.3%) |
| Dec 2007 | $20.00 M(-65.3%) | $19.23 M(+6624.1%) | $20.00 M(-65.7%) |
| Sep 2007 | - | $286.00 K(+210.9%) | $58.28 M(+0.5%) |
| Jun 2007 | - | $92.00 K(-76.3%) | $57.99 M(+0.1%) |
| Mar 2007 | - | $389.00 K(-99.3%) | $57.95 M(+0.7%) |
| Dec 2006 | $57.57 M(+26.0%) | $57.51 M(<-9900.0%) | $57.57 M(+25.9%) |
| Sep 2006 | - | -$1000.00(-102.0%) | $45.74 M(-0.0%) |
| Jun 2006 | - | $49.00 K(+250.0%) | $45.75 M(+0.1%) |
| Mar 2006 | - | $14.00 K(-100.0%) | $45.70 M(+0.0%) |
| Dec 2005 | $45.69 M(-36.0%) | $45.68 M(>+9900.0%) | $45.69 M(>+9900.0%) |
| Sep 2005 | - | $8000.00(-900.0%) | $32.00 K(+33.3%) |
| Jun 2005 | - | -$1000.00(-50.0%) | $24.00 K(-4.0%) |
| Mar 2005 | - | -$2000.00(-107.4%) | $25.00 K(-100.0%) |
| Dec 2004 | $71.43 M(+277.0%) | $27.00 K(>+9900.0%) | $71.43 M(+1.5%) |
| Sep 2004 | - | $0.00(0.0%) | $70.37 M(-22.1%) |
| Jun 2004 | - | $0.00(-100.0%) | $90.35 M(0.0%) |
| Mar 2004 | - | $71.40 M(-6985.5%) | $90.35 M(+376.8%) |
| Dec 2003 | $18.95 M(+72.9%) | -$1.04 M(-105.2%) | $18.95 M(-5.2%) |
| Sep 2003 | - | $19.99 M(>+9900.0%) | $19.99 M(>+9900.0%) |
| Jun 2003 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2003 | - | $0.00 | $0.00 |
| Dec 2002 | $10.96 M | - | - |
FAQ
- What is Oncternal Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual CFF year-on-year change?
- What is Oncternal Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly CFF year-on-year change?
- What is Oncternal Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM CFF year-on-year change?
What is Oncternal Therapeutics annual cash flow from financing activities?
The current annual CFF of ONCT is $1.07 M
What is the all time high annual CFF for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual cash flow from financing activities is $114.18 M
What is Oncternal Therapeutics annual CFF year-on-year change?
Over the past year, ONCT annual cash flow from financing activities has changed by -$8.51 M (-88.85%)
What is Oncternal Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ONCT is $0.00
What is the all time high quarterly CFF for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly cash flow from financing activities is $99.39 M
What is Oncternal Therapeutics quarterly CFF year-on-year change?
Over the past year, ONCT quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Oncternal Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ONCT is -$88.00 K
What is the all time high TTM CFF for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM cash flow from financing activities is $114.64 M
What is Oncternal Therapeutics TTM CFF year-on-year change?
Over the past year, ONCT TTM cash flow from financing activities has changed by $0.00 (0.00%)